PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Mathematical Sciences, University of Liverpool, Liverpool, UK.\', \'Centre for Global Vaccine Research, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.\', \'Graphnet Health, Milton Keynes, UK.\', \'Institute of Population Health, University of Liverpool, Liverpool, UK.\', \'Department of Health Data Science, University of Liverpool, Liverpool, UK.\', \'Department of Mathematics and School of Health Sciences, University of Manchester, Manchester, UK.\', \'Joint Universities Pandemic and Epidemiological Research, Manchester, UK.\', \'Department of Mathematical Sciences, University of Liverpool, Liverpool, UK. kjs@liverpool.ac.uk.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1186/s12879-022-07239-z
?:hasPublicationType
?:journal
  • BMC infectious diseases
is ?:pmid of
?:pmid
?:pmid
  • 35307024
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.576
?:rankingScore_hIndex
  • 80
is ?:relation_isRelatedTo_publication of
?:title
  • Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all